Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $9M Series A financing. Participants include Yissum Research Development Company, Pontifax and Clal Biotechnology Industries.

Galantos Pharma (Germany) a clinical-stage biopharmaceutical company focused on acetylcholinesterase modulation for the treatment of Alzheimer’s disease, closed a $5.7M Series C financing. Participants include VRP Rhineland Palatinate Fund, KfW Bankengruppe, F.I.B. Frankfurter Investmentbank, WFT Ventures and High-Tech Gründerfonds.

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

Cognition (Pittsburgh, PA) a preclinical-stage pharmaceutical company focused on Alzheimer’s and other neurodegenerative diseases, closed a $1.2M Series A financing. Participants include Ogden CAP, M5Invest Partners, Pittsburgh Life Sciences Greenhouse and Innovation Works.

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

AC Immune (Switzerland) an early-stage company developing therapeutics treatment for Alzheimer’s leveraging vaccines, antibodies and small molecules, closed a $34.6M Series C financing. Participants include undisclosed.

Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.

Satori Pharmaceuticals (Cambridge, MA) an early-stage neuroscience company focused on the discovery and development of therapies for Alzheimer’s, Parkinson’s disease and other neurodegenerative disorders closed a $22M Series B financing. Participants include InterWest Partners, Prospect Venture Partners, New Enterprise Associates and PureTech Ventures.

Accera (Broomfield, CO) a biotechnology company developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells, closed a $35M Series C financing. Participants include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.